Summit Therapeutics Inc. - 8-K Filing
Summit Therapeutics initiates global Phase III HARMONi-10 trial evaluating ivonescimab against durvalumab for Stage III non-small cell lung cancer.
Tickers: $SMMT
Summit Therapeutics initiates global Phase III HARMONi-10 trial evaluating ivonescimab against durvalumab for Stage III non-small cell lung cancer.
Tickers: $SMMT